ACLARIS THERAPEUTICS INC (ACRS) Stock Price, Quote, News and Overview
NASDAQ:ACRS - Nasdaq - US00461U1051 - Common Stock - Currency: USD
ACRS Quote, Performance and Key Statistics
ACLARIS THERAPEUTICS INC
NASDAQ:ACRS (1/30/2025, 4:00:47 PM)
After market: 2.39 0 (0%)2.39
+0.03 (+1.27%)
The current stock price of ACRS is 2.39 USD. In the past month the price decreased by -13.55%. In the past year, price increased by 95.04%.
ACRS Latest News, Press Releases and Analysis
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
Aclaris Therapeutics announces formation of new scientific advisory board...
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls
Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...
ACRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 80.95 | 781.51B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.73 | 379.02B | ||
| JNJ | JOHNSON & JOHNSON | 15.3 | 368.05B | ||
| MRK | MERCK & CO. INC. | 16.63 | 250.31B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.7 | 220.92B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.04 | 209.42B | ||
| PFE | PFIZER INC | 10.43 | 152.50B | ||
| SNY | SANOFI-ADR | 12.99 | 135.76B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.55 | 119.95B | ||
| ZTS | ZOETIS INC | 29.98 | 77.92B | ||
| GSK | GSK PLC-SPON ADR | 8.54 | 72.14B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 22.83 | 43.43B |
Related stock screener links
About ACRS
Company Profile
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 91 full-time employees. The company went IPO on 2015-10-07. The firm has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The firm's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The firm's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Company Info
ACLARIS THERAPEUTICS INC
701 Lee Road, Suite 103
Wayne PENNSYLVANIA 19087 US
CEO: Neal Walker
Employees: 89
Company Website: https://www.aclaristx.com/
Investor Relations: https://www.aclaristx.com/#!investors/juser
Phone: 14843247933
ACRS FAQ
What is the stock price of ACRS?
The current stock price of ACRS is 2.39 USD.
What is the symbol for ACLARIS THERAPEUTICS INC stock?
The exchange symbol of ACLARIS THERAPEUTICS INC is ACRS and it is listed on the Nasdaq exchange.
On which exchange is ACRS stock listed?
ACRS stock is listed on the Nasdaq exchange.
Is ACRS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ACRS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ACRS.
Does ACRS stock pay dividends?
ACRS does not pay a dividend.
When does ACRS stock report earnings?
ACRS will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of ACRS?
ACRS does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
What is the Short Interest ratio of ACRS stock?
The outstanding short interest for ACRS is 5.2% of its float.
ACRS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ACRS. When comparing the yearly performance of all stocks, ACRS is one of the better performing stocks in the market, outperforming 93.29% of all stocks.
ACRS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ACRS. ACRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ACRS Financial Highlights
Over the last trailing twelve months ACRS reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS decreased by 68.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.29% | ||
| ROE | -28.43% | ||
| Debt/Equity | 0 |
ACRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ACRS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 43.83% and a revenue growth -36.68% for ACRS